This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Infertility	Phosphoinositide 3-kinase (PI3K); phosphatase and tensin homolog deleted on chromosome 10 (PTEN; MMAC1; TEP1); protein kinase B (PKB; PKBA; AKT; AKT1)	<p>Mouse studies suggest AS101 could help prevent cyclophosphamide-induced depletion of ovarian follicles, which leads to infertility. In female mice, cyclophosphamide enhanced Pi3k-Pten-Akt signaling and decreased primordial ovarian follicles compared with vehicle. In female mice, the Pi3k-Pten-Akt pathway inhibitor AS101 decreased cyclophosphamide-induced follicle loss and rescued fertility compared with saline. Next steps include evaluating the ability of AS101 to protect ovarian follicles in nonhuman primates. BioMAS Ltd.'s AS101 is in Phase II testing to prevent chemotherapy-associated hematological toxicity. Cyclophosphamide is a generic chemotherapeutic.</p> <p>SciBX 6(23); doi:10.1038/scibx.2013.578 Published online June 13, 2013</p>	<p>Patented; available for licensing from BioMAS Ltd.</p> <p>Contact: Ayelet Dilion-Mashiah, BioMAS Ltd., Jerusalem, Israel e-mail: ayelet@biomas-pharma.com</p>	<p>Kalich-Philosoph, L. <i>et al. Sci. Trans. Med.</i>; published online May 15, 2013; doi:10.1126/scitranslmed.3005402</p> <p>Contact: Dror Meirow, Tel Aviv University, Tel Aviv, Israel e-mail: meirow@post.tau.ac.il</p>